fda stops tirzepatide compounding ban on compounded tirzepatide: Switch to name brand medications is fda stopping compounded tirzepatide
Description
Results from Eli Lillys SURMOUNT-2 trial are in, and they further confirmed that its GLP-1 agonist tirzepatide (aka Mounjaro) drives meaningful weight loss among obese or overweight adults with type 2 diabetes

Mechanism: GLP-1 receptor agonist
She co-writes The Readout newsletter, and co-hosts STATs weekly biotech podcast, The Readout Loud

I take 12.5 weekly

J., Taype-Rondan, A., Tapia, J

It pushes usage toward name-brand, FDA-approved possibilities for weight control.